Grace Therapeutics, Inc. (GRCE)
NASDAQ: GRCE · Real-Time Price · USD
4.290
+0.170 (4.13%)
At close: Feb 27, 2026, 4:00 PM EST
4.250
-0.040 (-0.93%)
After-hours: Feb 27, 2026, 7:56 PM EST

Grace Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Apr - Mar.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Feb '26 Mar '25 Mar '24 Mar '23 Mar '22 Mar '21
6631322154120
Market Cap Growth
88.59%-2.84%56.90%-62.03%-55.00%250.73%
Enterprise Value
48207-10892
Last Close Price
4.292.283.422.767.3228.80
PS Ratio
-----612.61
PB Ratio
1.020.470.520.300.502.16
P/TBV Ratio
4.251.812.581.102.122.16
EV/Sales Ratio
-----470.71
Debt / Equity Ratio
---0.010.000.00
Net Debt / Equity Ratio
-0.29-0.33-0.37-0.40-0.40-1.09
Net Debt / EBITDA Ratio
1.661.332.041.523.876.19
Net Debt / FCF Ratio
1.841.491.861.722.524.22
Asset Turnover
-----0.01
Quick Ratio
14.5611.5314.098.4113.5638.80
Current Ratio
14.9611.7714.268.5913.8939.50
Return on Equity (ROE)
-10.22%-14.91%-19.82%-48.15%-11.98%-57.33%
Return on Assets (ROA)
-10.84%-14.35%-9.25%-10.96%-7.94%-15.70%
Return on Capital Employed (ROCE)
-16.70%-23.80%-15.70%-24.00%-9.70%-17.60%
Earnings Yield
-9.01%-30.59%-39.92%-206.80%-18.17%-16.39%
FCF Yield
-15.26%-47.65%-38.38%-77.64%-31.90%-11.98%
Buyback Yield / Dilution
-36.09%-26.85%-28.16%-21.09%-148.46%-40.25%
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q